Skip to main
We’re doing some system maintenance

Posts & Investments - #biotech

Invested in Agilent Technologies
My friend works in biotech and said this might be good so we are making a small investment to test the theory #youneverknow #startsmall #biotech #biotechnology #science
Invested in Omeros
OMER’s narsoplimab is one of the most promising candidates in all of biotech. The commercial opportunity has been validated by the success of ALXN’s Soliris, and given the similar patient pools for the indications targeted by these two drugs. OMER will price narsoplimab close to Soliris’ annual price tag of $500K+, at a price of $250K/yr and 25% market share #longterm #biotech
👉Buffett’s Berkshire Hathaway Suddenly Has An Insatiable Appetite For Stocks #Companies #News #Business #StocksSee more
Sold Sangamo TherapeuticsInvested for 171 days
Recouping costs to reinvest elsewhere. Zinc finger genome editing/silencing is still a viable option for #medicine in the future, but we still have a long way to go. Right now it’s best uses are for #research #science #biotech but I’ll be keeping an eye out!
Own your future.
Build your portfolio.
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.